Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Ampersand Biomedicines Presents Preclinical Data on AMP-410, a Novel Anti-VEGF/4-1BB Bifunctional AND-Body™ Therapeutic, at AACR 2025
-
Ascentage Pharma Presents Results from Five Preclinical Studies at 2025 American Association of Cancer Research (AACR) Annual Meeting, Highlighting Strong Synergistic Effects of Olverembatinib Combine
-
Globavend Receives Government Non-Dilutive Grant Funding Approval
-
DecisionDx®-Melanoma Test Ordered More Than 200,000 Times for Patients Diagnosed with Cutaneous Melanoma
-
Village Farms International Takes Top Honors at the 2025 Stevie® Awards
-
Osisko Development Announces Optimized Feasibility Study for Permitted Cariboo Gold Project with C$943 Million After-Tax NPV5% and 22.1% IRR at US$2,400/oz Base Case Gold Price; at US$3,300/oz Spot Go
-
Senti Bio’s SENTI-202, a First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, Demonstrates Positive Preliminary Clinical Results in the Treatment of Patients
-
ADMA Biologics Announces U.S. FDA Approval of Innovative Production Yield Enhancement Process
-
AAVantgarde appoints Mr. Rasmus Holm-Jorgensen as Chief Financial Officer
-
Green Thumb to Open RISE Dispensary Ocala in Florida, its 104th Retail Location in the Nation, on April 29
-
Benevity Appoints Industry’s First Chief Artificial Intelligence Officer
-
Widmer Brothers Brewing Celebrates 40th Anniversary
-
Prairie Operating Co. Begins Completion of the Opal Coalbank Pad, Acquired from Bayswater
-
Lungpacer to Showcase the Potential of Novel Technologies to Improve Lung, Heart, and Brain Health in Ventilated Patients
-
Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
-
CW Petroleum Corp (OTCQB: CWPE) Reports Revenues for Year-End 2024, Q1-2025, No Effects from Tariffs
-
Syndax to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 5, 2025
-
Aktsiaselts Infortar Investor Webinar introducing the results of the Q1 2025
-
AccuStem Sciences, Inc. and EmeritusDX Announce Partnership to Commercialize MSC Test for Lung Cancer Screening
-
Signify share repurchase period update
-
Avacta Therapeutics Presents Preclinical and Translational Data from pre|CISION® Platform Candidates at 2025 AACR Annual Meeting
-
Purespring Therapeutics granted European Medicines Agency (EMA) orphan drug designation for PS-002 for the treatment of patients with primary IgA nephropathy (IgAN)
-
Roper Technologies announces first quarter financial results
-
Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution)
-
Form 8.5 (EPT/RI) - Inspired Plc
-
Form 8.5 (EPT/RI) - Anexo Group Plc
-
Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting
-
TDC NET A/S – Publication of Prospectus Supplement
-
Oma Savings Bank Plc to publish its January-March 2025 interim report on 5 May 2025
-
FINGRID GROUP – MANAGEMENT’S REVIEW 1.1.−31.3.2025
-
BYDFi Lists SIGN/USDT Trading Pair with $5,000 Prize Pool
-
Kraken Robotics Reports 2024 Financial Results
-
Preliminary data on early redemptions (prepayments)
-
Dassault Aviation: Signature of the Rafale Marine contract for India
-
Nordic Fibreboard AS Audited Annual Report 2024
-
UAB "Atsinaujinančios energetikos investicijos" aims to extend the Company's operational term and to adopt a decision regarding the approval of the terms for a planned new bond program with a nominal
-
Transactions in connection with share buy-back program
-
Man Group PLC : Form 8.3 - Dalata Hotel Group plc
-
T1 Energy Welcomes Key Additions to Leadership Team
-
MEXC DEX+ Unveils Upgrade: One-Click Wallet Access Redefines Web3 Trading
-
Provident Financial Holdings Reports Third Quarter of Fiscal Year 2025 Results
-
Liberty Gold Announces the Retirement of Cal Everett, CEO & Director and the Appointment of Dr. Jon Gilligan as new President and Chief Executive
-
Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7
-
Tyton Partners Releases New Report on Affordable Access Programs for Course Materials
-
Man Group PLC : Form 8.3 - Urban Logistics REIT plc
-
Heineken Holding N.V. reports transactions under its current share buyback programme
-
Heineken N.V. reports the progress of transactions under its current share buyback programme
-
Transactions in connection with share buyback programme
-
Man Group PLC : Form 8.3 - LondonMetric Property plc
-
Net Asset Value(s)

